Pharmaceutical

Menarini signs agreement for Astellas’s rheumatoid arthritis therapy

Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to treat rheumatoid arthritis.

Sep 13, 2023 - 20:00
Menarini signs agreement for Astellas’s rheumatoid arthritis therapy
Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to treat rheumatoid arthritis.
Read the original article

Tags:

Previous Article

Signal: Roche to refile subcutaneous Tecentriq with FDA after UK approval

Next Article

Dewpoint and Chemify partner for cancer drug discovery

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

FDA expands Pfizer’s RSV vaccine label to include all h...

Oct 24, 2024

Explainer: Labour has been elected in the UK – now what?

Explainer: Labour has been elected in the UK – now what?

Jul 14, 2024

STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits

STAT+: A controversial new study examines traditional C...

Oct 24, 2023